Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dermacia, Inc. was a biotechnology-focused cosmeceutical company primarily known for developing and marketing Lycogel, a breathable camouflage and skincare line designed for post-operative recovery. The company's core innovation was its Triple Silica Gel technology, which created a breathable matrix allowing oxygen, moisture, and nutrients to reach the skin while providing coverage for redness and bruising. This technology was marketed as a significant advancement for patients recovering from aesthetic procedures such as laser resurfacing and chemical peels. Although the company achieved commercial status with its product line, it faced significant financial and legal challenges, eventually leading to bankruptcy and the sale of its assets. Today, the Lycogel brand continues to exist under different ownership, while the original Dermacia entity is inactive.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dermacia.